Τίτλος:
Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
The antiphospholipid syndrome (APS) is defined by the presence of thrombosis and/or pregnancy morbidity in combination with the persistent presence of circulating antiphospholipid antibodies: lupus anticoagulant, anticardiolipin antibodies and/or anti-β2-glycoprotein I antibodies in medium to high titers. The management of thrombosis in patients with APS is a subject of controversy. This set of recommendations is the result of an effort to produce guidelines for therapy within a group of specialist physicians in Cardiology, Neurology, Hematology, Rheumatology and Internal Medicine, with a clinical and research focus on APS. © The Author(s), 2011.
Συγγραφείς:
Ruiz-Irastorza, G.
Cuadrado, M.J.
Ruiz-Arruza, I.
Brey, R.
Crowther, M.
Derksen, R.
Erkan, D.
Krilis, S.
Machin, S.
Pengo, V.
Pierangeli, S.
Tektonidou, M.
Khamashta, M.
Περιοδικό:
Lupus Science and Medicine
Λέξεις-κλειδιά:
acetylsalicylic acid; acetylsalicylic acid plus hydroxychloroquine sulfate; anticoagulant agent; beta2 glycoprotein 1 antibody; cardiolipin antibody; heparin; hydroxychloroquine; hydroxymethylglutaryl coenzyme A reductase inhibitor; lupus anticoagulant; oral contraceptive agent; phospholipid antibody; placebo; warfarin, antibody titer; anticoagulant therapy; antiphospholipid syndrome; artery thrombosis; cardiologist; cardiovascular risk; clinical research; clinical trial; conference paper; disease association; evidence based practice; heart atrium fibrillation; hematologist; human; internal medicine; international normalized ratio; low drug dose; medical specialist; morbidity; neurologist; physician; practice guideline; pregnancy; priority journal; rheumatology; stroke; systemic lupus erythematosus; thrombosis; thrombosis prevention; venous thromboembolism, Advisory Committees; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Clinical Trials as Topic; Congresses as Topic; Female; Humans; Pregnancy; Texas; Thrombosis
DOI:
10.1177/0961203310395803
